Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice DOI Creative Commons

Huijie Yang,

Ying Xie, Shuyan Li

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: June 16, 2024

Mucosal immunity plays a crucial role in combating and controlling the spread of highly mutated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recombinant subunit vaccines have shown safety efficacy clinical trials, but further investigation is necessary to evaluate their feasibility as mucosal vaccines. This study developed SARS-CoV-2 vaccine using spike (S) proteins from prototype strain omicron variant, along with cationic chitosan adjuvant, systematically evaluated its immunogenicity after both primary booster immunization mice. Primary through intraperitoneal intranasal administration S protein elicited cross-reactive antibodies against strains, well delta variants, particularly strong effects observed vaccination. In context following inactivated vaccines, omicron-based resulted broader more robust neutralizing antibody response serum mucosa compared vaccine, enhancing protection different variants. These findings indicate that vaccination has potential trigger stronger during immunization, making it promising strategy pathogens.

Language: Английский

Protein Nanoparticles as Vaccine Platforms for Human and Zoonotic Viruses DOI Creative Commons
Kush Kumar Pandey, Bikash R. Sahoo, Asit K. Pattnaik

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(6), P. 936 - 936

Published: June 9, 2024

Vaccines are one of the most effective medical interventions, playing a pivotal role in treating infectious diseases. Although traditional vaccines comprise killed, inactivated, or live-attenuated pathogens that have resulted protective immune responses, negative consequences their administration been well appreciated. Modern evolved to contain purified antigenic subunits, epitopes, antigen-encoding mRNAs, rendering them relatively safe. However, reduced humoral and cellular responses pose major challenges these subunit vaccines. Protein nanoparticle (PNP)-based garnered substantial interest recent years for ability present repetitive array antigens improving immunogenicity enhancing responses. Discovery characterisation naturally occurring PNPs from various living organisms such as bacteria, archaea, viruses, insects, eukaryotes, computationally designed structures approaches link PNPs, paved way unprecedented advances field vaccine technology. In this review, we focus on some widely used optimally suitability promising platforms displaying native-like human viral Such hold great promise combating emerging re-emerging diseases efficacy safety.

Language: Английский

Citations

5
Encapsulin nanoparticle-conjugated p54 protein boosts immune responses against African swine fever virus DOI
Yue Zhang, Yi Ru, Longhe Zhao

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: unknown, P. 143912 - 143912

Published: May 1, 2025

Language: Английский

Citations

0
Advances in protein subunit vaccines against H1N1/09 influenza DOI Creative Commons
Yu Zhang,

Jingyao Gao,

Wenqi Xu

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 22, 2024

The A/H1N1pdm09 influenza virus, which caused the 2009 pandemic, has since become a recurring strain in seasonal outbreaks. Given ongoing threat of influenza, protein subunit vaccines have garnered significant attention for their safety and effectiveness. This review seeks to highlight latest developments that specifically target virus. It will also examine structure replication cycle A viruses compare different types vaccines. Additionally, address key aspects H1N1 vaccine development, such as antigen selection, expression systems, use adjuvants. role animal models evaluating these be discussed. Despite challenges like antigenic variability complexities production distribution, remain promising option future prevention efforts.

Language: Английский

Citations

2
Protein Nanoparticles as Viral Vaccine Platforms DOI Open Access
Kush Kumar Pandey, Bikash R. Sahoo, Asit K. Pattnaik

et al.

Published: May 10, 2024

Vaccines are one of the most effective medical interventions, playing a pivotal role in treating infectious diseases. Although traditional vaccines comprising killed, inactivated, or live attenuated pathogens have resulted protective immune responses, negative consequences their administration been well-appreciated. Modern evolved to contain purified antigenic proteins, epitopes, antigen-encoding mRNAs, rendering them relatively safe. However, reduced humoral and cellular responses pose major challenges modern vaccine platforms. Protein nanoparticle (PNP)-based garnered substantial interest recent years for ability present repetitive array antigens improving immunogenicity enhancing responses. Discovery characterization naturally occurring PNPs from various living organisms such as bacteria, archaea, viruses, insects, eukaryotes, well computationally designed structures approaches link paved way unprecedented advances field technology. In this review, we focus on some widely used optimally suitability promising platforms displaying native-like viral Such hold great promise combating emerging re-emerging diseases efficacy safety.

Language: Английский

Citations

1
Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice DOI Creative Commons

Huijie Yang,

Ying Xie, Shuyan Li

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: June 16, 2024

Mucosal immunity plays a crucial role in combating and controlling the spread of highly mutated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recombinant subunit vaccines have shown safety efficacy clinical trials, but further investigation is necessary to evaluate their feasibility as mucosal vaccines. This study developed SARS-CoV-2 vaccine using spike (S) proteins from prototype strain omicron variant, along with cationic chitosan adjuvant, systematically evaluated its immunogenicity after both primary booster immunization mice. Primary through intraperitoneal intranasal administration S protein elicited cross-reactive antibodies against strains, well delta variants, particularly strong effects observed vaccination. In context following inactivated vaccines, omicron-based resulted broader more robust neutralizing antibody response serum mucosa compared vaccine, enhancing protection different variants. These findings indicate that vaccination has potential trigger stronger during immunization, making it promising strategy pathogens.

Language: Английский

Citations

0